2026-07-16 04:47
•
Investing.com
Johnson & Johnson experienced a mid-July stock pullback of approximately 2% following earnings results, but analysts view this as a buying opportunity. The company reported strong Q2 results with $25.31B in revenue (up 6.8% YOY), beat EPS expectations at $2.90, and raised full-year guidance. With a diversified portfolio, robust pipeline, upcoming orthopedics spin-off, and Dividend King status, the company is positioned for sustained growth despite talc litigation risks.
Axe note: Johnson & Johnson’s solid Q2 and raised guidance make its recent 2% drop an attractive entry point.